Core Viewpoint - The company reported a revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - The earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Revenue Performance - The revenue growth was primarily driven by strong sales performance of core brands, particularly the branded pharmaceutical segment's He Ji Gong and the traditional Chinese medicine segment's Bao Ji Wan [1] - Focused brand management and effective market promotion execution contributed to the sales performance [1] Business Segments - The Chinese medicine formula granules business showed stable performance, continuously contributing to the brand health business group [1]
健倍苗苗公布中期业绩 公司权益持有人应占溢利约为1.15亿港元 同比增加约20.0%